Treatment Approach Before the Discovery of IDH-Inhibitors

UCSF neuro-oncologist Jennie Taylor, MD, MPH, explains the treatment algorithm that physicians used for managing low-grade gliomas prior to August 6, 2024 — when the U.S. Food and Drug Administration approved the first IDH inhibitor for brain tumors. Treatment options included surgery, chemotherapy, radiation therapy, and active surveillance and were based on IDH mutation status.